|
|
|
| Efficacy Study of Inhaled Therapy with Symbicort Turbulaler in the Treatment of Patients with Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease |
| SONG Zhonghua |
| Shandong Third Hospital, Shandong Ji'nan 250031, China |
|
|
|
|
Abstract Objective: To explore the effect of inhaled therapy with symbicort turbulaler in the treatment of patients with lung cancer complicated with chronic obstructive pulmonary disease. Methods: 78 cases of COPD patients with lung cancer treated in the hospital respiratory department in April 2016 to June 2017 were selected as the study objects. According to the principle of random control, the patients were divided into the observation group (39 cases) and the control group (39 cases).The control group was given conventional basic treatment and symptomatic treatment for lung cancer and COPD stable period. On the basis of this, the observation group was given inhaled therapy with symbicort turbulaler.1 intake / time, 2 times /d, 1 times in the morning and evening, regular treatment for 3 months, regular follow-up during treatment. Results: There was no difference in the two lung function indexes, inflammatory factors and quality of life scores before treatment (P>0.05). After treatment, the FEV1% and FEV1/FVC indexes of the two groups were significantly improved, and the observation group was significantly higher than the control group (P<0.05). IL-6 and IL-8 indicators of two groups were significantly reduced.The observation group was significantly lower than the control group (P<0.05). During the follow-up period, the incidence of adverse reactions in the observation group was 17.95%, and the incidence of adverse reactions in the control group was 12.82%, the difference was not statistically significant (P>0.05). Conclusion: Inhaled therapy with symbicort turbulaler can significantly improve lung function and quality of life in patients with chronic obstructive pulmonary disease with stable stage of lung cancer, and is worthy of promotion.
|
|
|
|
|
|
[1] 庞军,黄蕊,王媛,等.沙美特罗联合孟鲁司特钠对支气管哮喘患儿肺功能的保护作用及NO ET IFN-γ水平的影响[J].河北医学,2018,(5):816~819.
[2] 陈欣,曹洁,陈宝元等.慢性阻塞性肺疾病患者肺组织中白细胞介素17的表达及其临床意义[J].中华医学杂志,2016,96(26):2086~2090.
[3] 罗秀员,胡央波.布地奈德联合孟鲁斯特钠治疗小儿支原体肺炎的疗效观察[J].中国基层医药,2016,23(8):1211~1214.
[4] 庞军,黄蕊,王媛,等.沙美特罗联合孟鲁司特钠对支气管哮喘患儿肺功能的保护作用及NO ET IFN-γ水平的影响[J].河北医学,2018,24(5):816~819.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,6(4):484~491.
[6] 刘莹,王圆圆,贾文青,等.肺癌患者血清p16、FHIT、APC基因甲基化检测[J].郑州大学学报(医学版),2017,52(1):51~54.
[7] Watson A, Bijos P, Ludwikowski R, et al. The potential to improve inhalation technique in patients with asthma or copd by switching from symbicort turbuhaler (budesonide + formoterol) to duoresp spiromax: estimated impact on the number and cost of unscheduled healthcare events in poland[J]. Value in Health, 2016, 19(7):A688~A688.
[8] 胡斌,张龙富,余荣环,等.布地奈德福莫特罗粉吸入治疗肺癌合并慢阻肺患者的临床疗效及对患者生活质量的影响[J].现代生物医学进展,2017,17(29):5686~5689. |
|
|
|
2018, Vol. 24 
